

Special Feature

Fujifilm Group Undergoing Transformation from Photographic Film to Healthcare

Initiatives in Healthcare Business Field, Fujifilm's Medium-to-Long-Term Growth Driver

Under VISION 2016, its medium-term management plan, Fujifilm is focusing on three business fields: healthcare, highly functional materials, and document. Of these, the healthcare business field has been expanded to encompass wide-ranging businesses relating to people's health, from diagnosis to prevention and treatment. Leveraging the Group's extensive range of products and services as well as the technologies accumulated to date, Fujifilm will work to further improve people's quality of life as a "comprehensive healthcare company."

Diagnosis

▶ For more details, please see page 18.

Having started out with the X-ray film that was launched soon after its founding, Fujifilm supplies medical equipment that includes the Fuji Computed Radiography (FCR) digital X-ray imaging diagnostic system that was the first in the world to bring to fruition the digitization of X-ray images for medical use; endoscope systems; ultrasound diagnostic equipment; and in-vitro diagnostic systems as well as the SYNAPSE medical-use picture archiving and communications systems (PACS).

1936



X-ray film

1971



Endoscope system

1983



Digital X-ray imaging diagnostic system FCR

1984



DRI-CHEM blood analysis system

1989



Dry imagers

1999



SYNAPSE medical-use picture archiving and communications systems (PACS)

2006



Ultrasound diagnostic equipment

2007



DR type X-ray imaging diagnostic system

Prevention

Drawing on its knowledge relating to collagen—the main raw material for photographic film—as well as antioxidation technologies that help prevent photos from fading and proprietary nanotechnologies that miniaturize the functional materials included in films while stabilizing dispersion, Fujifilm started to sell functional cosmetics and supplements and entered the prevention field in 2006. Fujifilm is expanding its lineup of highly unique products such as the ASTALIFT Series that leverage its technologies.

2006



Functional cosmetics

2006



Supplements

2014



Hair care products

Treatment

▶ For more details, please see page 20.

In 2008, Fujifilm acquired Toyama Chemical Co., Ltd., and made its full-scale entry into the treatment field. By acquiring a biopharmaceutical contract manufacturing company from U.S.-based Merck & Co., Inc., in 2011 and other moves, Fujifilm has been expanding its pharmaceuticals business. Also, in the field of regenerative medicine, Fujifilm made Japan Tissue Engineering Co., Ltd., and Cellular Dynamics International, Inc., consolidated subsidiaries in 2014 and 2015, respectively, and is making progress in expanding its business fields.

2008



Small molecule drugs (Toyama Chemical Co., Ltd.)

2011



Contract manufacturing of biopharmaceuticals (FUJIFILM Diosynth Biotechnologies)

2014



Autologous cultured epidermis (Japan Tissue Engineering Co., Ltd.)

2015



iPS cells (Cellular Dynamics International, Inc.)